Pakistan Post-Registration Variation Fees for Medical Devices

1. Key takeaways

Pakistan splits “changes” into two fee pathways: post-enlistment / post-registration variations are charged separately under the variation entries of Schedule C, while general changes are charged at 50% of the relevant fee. The key to classification is not the size of the change but which entry it falls under. The core sequence of change management is therefore: classify first, then price, then submit.

The reason this sequence matters is that misclassification is discovered late and corrected expensively. A change filed under the wrong entry produces deficiency correspondence, a fresh fee assessment, and a delay that lands precisely when the market needs the updated material. Classifying at intake — before any filing decision — converts variation management from a reactive chore into a controlled process with known costs and known timelines, which is what a five-year certificate life demands. It also gives the quality system a clean audit trail: every change on record can be traced to a classification decision, a fee, and a submission, which is exactly what an inspector will ask to see.

2. Legal basis

The table below summarises the fee provisions and the procedural rules that govern post-enlistment and post-registration changes in Pakistan.

Two features of this framework shape day-to-day practice. The first is that the 50% rule for general changes is written into the notes to Schedule C, so the cost of a minor change is calculable the moment the underlying fee is known. The second is that the online channel is now mandatory, which means the variation file must be portal-ready — structured documents, correct references, and a fee challan — rather than assembled for a paper submission. Since 21 July 2025 a variation dossier that is not prepared for the portal is not merely inconvenient; it is simply not accepted, so the internal document standards have to be aligned with the portal’s requirements in advance.

3. Expert insights

Insight 1: the 50% ratio is worth remembering on its own. It means that even small changes need a budget. Many manufacturers treat a change as something to “fix in passing”, and because there is no budget and no schedule, the change is postponed again and again, until it turns into a compliance problem of labels no longer matching the approved versions. The irony is that the change itself was cheap relative to the exposure it created; the missing ingredient was never money but planning. A useful internal rule is that no change decision leaves the design or production change-control meeting without a regulatory line item attached, so the fee and the timeline are priced into the change at the same moment as the technical work.

Insight 2: Rule 14(6) is the red line for changes. Labels and prescribing information must be consistent with the versions approved in the country of origin or the reference country. Any localised change at the label level must first be checked back against the approved version in the country of origin or the reference country, otherwise the change itself creates a new inconsistency. This rule quietly connects Pakistan’s variation system to the manufacturer’s home-market regulatory record: a local edit that has no counterpart in the approved master artwork is not a neutral adjustment but a deviation. The practical discipline is to treat the master approved artwork as the single source of truth and to derive every Pakistani label from it under change control. Where the manufacturer ships to multiple markets, aligning the change calendar across markets at the same time prevents the same label edit from being assessed three times under three different national rules.

Insight 3: changes and renewal stack on top of each other. For changes arising close to renewal, practice generally requires the changes to be resolved before the renewal is processed, and both time and fees then stack up. Consolidating them into a single round of handling saves a full procedural cycle. Planning the last year of each certificate with this stacking in mind — screening for pending changes early, resolving them in one coordinated round — is one of the simplest ways to protect the renewal date itself. It also spreads the work: a coordinated round handled early is a planned project, while the same round handled in the renewal window is an emergency with a deadline attached.

4. Practical recommendations

GRZAN requires its clients to maintain a “change trigger list”: the common change scenarios (manufacturer name / address change, standard version update, label artwork update, packaging specification change, reissue of the letter of authorisation, change in product composition) are laid out in a table, and each item is marked with its classification, whether approval is needed, the fee, and the time it takes. The list is placed inside the quality system documentation, so the quality department can check against it the moment any action arises. Because the list lives where the change actually originates, it catches events at the moment they are decided rather than months later when the paperwork surfaces, and each new type of change encountered on a project is added to the list so the tool keeps improving with use. Over a multi-product portfolio, the accumulated list becomes the fastest way to brief a new team member, because it compresses years of variation practice into a single reference table.

5. Verification checklist

• □ Change trigger list established and classifications assigned
• □ Distinction made between post-enlistment / post-registration variations and general changes (50%)
• □ Label changes checked back against the approved version in the country of origin / reference country (Rule 14(6))
• □ Confirmed that changes are processed only through the e-Services portal
• □ Time and cost impact of changes stacking with renewal assessed

Regulatory information verified as of 28 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across South Asia, including Pakistan. Our team prepares dossiers to DRAP expectations, manages eCTD-format submissions and deficiency responses, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com